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Background: Most people with febrile illness are treated in the private drug retail sector. Ghana was among
nine countries piloting the Global Fund Affordable Medicines Facility – malaria (AMFm). AMFm aimed to:
increase artemisinin combination therapy (ACT) affordability; increase ACT availability; increase ACT use; and
‘crowd out’ artemisinin monotherapies.
Methods: Three censuses were carried out 2 months before (2010), 2 months after and 2.5 years after (2013)
the ﬁrst co-paid ACTs to assess changes in antimalarial (AM) availability and price in private retail shops in a
Ghanaian rural district to assess the sustainability of the initial gains. Supply, stock-out and cost were explored.
Results: Of 62 shops in the district, 56 participated with 398, 388 and 442 brands of AMs in the shops during
the 3 censuses. The proportion of ACTs increased over the period while monotherapies reduced. Herbal-
based AM preparations comprised 40–45% of AMs in stock with minimal variation over the period. ACTs
were the most sold AM type for all ages but overall buying and selling prices of Quality Assured-ACTs
increased by 40–100%.
Conclusions: Initial gains in ACT availability were sustained, but not improved on 2.5 years after AMFm.
Widespread availability of unproven herbal medicines is a concern; AMFm had little impact on this.
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Introduction
In common with much of Africa, the majority of adults and chil-
dren with febrile illness in Ghana, including the poorest, are trea-
ted in the private retail sector.1–3 Accepting this reality, and on
advice from many economic commentators that subsidies
would be needed, the Global Fund introduced the innovative
Affordable Medicines Facility – malaria (AMFm) initiative, which
subsidised high-quality Artemisinin Combination Therapy (ACT)
drugs to try to ensure that those buying from the sector had
access to effective combinations.4 The four main objectives of
AMFm were to: increase ACT affordability; increase ACT availabil-
ity; increase ACT use, including among vulnerable groups; and
‘crowd out’ oral artemisinin monotherapies. AMFm was consid-
ered audacious both in its aims and scope, and was not without
controversy, with some commentators very skeptical that an
intervention in the private sector was wise. Initial trial and
evaluation evidence was however broadly supportive.5–8
Ghana was among the nine countries that piloted the ﬁrst
phase of the strategy. Ghana was also the ﬁrst country to
receive the subsidised ACTs (called ‘co-paid’), and availability of
ACTs increased from 31% to 83% nationwide. The price of ACTs
dropped from about US$7 to US$0.75 for adults and from US$5
to US$0.5 for children by December 2011 according to initial
assessments.9 Experience elsewhere suggested a mixed picture;
for example in Tanzania, although availability was widespread,
there were variations across districts not based on remoteness
and average prices fell from US$1.03 to US$0.81 over the study
period, even though the government recommended retail price
for the subsidised ACTs was US$0.64.10 In Nigeria and Ghana,
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Bate et al found a few months after introduction of the subsi-
dised ACTS that they were lower in price than many of the other
drugs collected, but by less than anticipated or stipulated by the
participating governments.11
Initial assessments were broadly positive, but initial assess-
ments undertaken after a major change often do not reﬂect
subsequent operational reality. The system can either revert
back towards the previous norm, or initial successes can be built
on. This study aimed to look at the effect in a typical Ghanaian
district over the change period, and then once the change had
become established practice. Chemical shops, the principal pri-
vate retail outlet for drugs in many remote areas were the focus
of the study. The study assessed changes in ACT availability in
the private retail shops at three different time periods; 2 months
before, 2 months after and 2.5 years after the ﬁrst co-paid ACTs
arrived in Ghana in August 2010. We also assessed prices of
antimalarials (AM) in the shops 2.5 years after AMFm in a rural
district in Ghana with an original ﬁxed co-paid ACT price of 1.50
Ghana cedis(ghs) (USD1.00), and the effect on availability of
artemisinin monotherapy and other antimalarial drugs in the
private drug retail shops.
Materials and methods
Study site and population
The study was carried out in the Dangme West District of
Ghana, a rural and deprived district with an estimated 2012
mid-year population of 130 570 based on the 2010 census and
recently divided into two separate administrative districts.12
Most of the population lives in scattered small communities of
less than 2000 people. Vehicular transport is unavailable in
many parts of the district and people have to walk long dis-
tances (approx. 2–6 h) to reach the nearest main road making
access to formal care difﬁcult. The district is typical of poor dis-
advantaged rural and semi-rural districts across the country.
Poverty is widespread. Health services are delivered from one
district hospital, four health centres, 13 Community Health
Planning and Services (CHPS) compounds and ﬁve private health
facilities. CHPS compounds are the lowest level of service deliv-
ery in the health system, where services are delivered by com-
munity health nurses (auxiliary nurses). The district hospital and
three of the health centres are located in the four largest towns
in the district. A total of 56 chemical sellers and 6 pharmacies
also sell pharmaceutical products and their diagnostic practice
is described elsewhere.12 Chemical sellers are regulated by law
and supervised by the Pharmacy Council, which also regulates
pharmacies. To be eligible to apply for a chemical seller’s license,
a person must possess a minimum qualiﬁcation of General
Certiﬁcate of Examination (GCE) Ordinary Level Certiﬁcate or a
Senior Secondary School (SSS) Certiﬁcate with basic knowledge
in healthcare delivery being an advantage. Applicants attend a
pre-licensing training organised by the council and the licenses
are renewed annually. The shops are by law allowed to supply
by retail, over-the-counter medicines to members of the public
in communities considered to be deprived by the Council. The
authorised medicines do not generally include antibiotics but do
include analgesics and antimalarials. The only antibiotic recently
included is co-trimoxazole. They obtain their medicines from the
same drug companies who supply medicines to pharmacies.
Earlier studies carried out in the district showed that for pre-
sumed ‘malaria’ in the household, the ﬁrst action taken in order
of the most common were home treatment, chemical seller,
health centre, hospital, drug peddler and traditional healer in
that order.13 Recent demographic surveillance data from the
district indicated that about 67% of all deaths took place at
home.14
Study design
The study involved carrying out three censuses in chemical
shops. The census involved the documentation of all the differ-
ent types of AM in the shops as well as the retail prices. The cen-
suses were carried out in 53 chemical shops and 3 pharmacies,
out of the total of 62 operating in the district. The selected
shops were also participating in an on-going trial. The ﬁrst cen-
sus took place 2 months before the AMFm strategy while the
remaining two, took place 2 months and 2.5 years after the
strategy had been implemented (Table 1).
At the time of the last census, a short survey was carried out
in the shops to ﬁnd out from the shop owners or regular atten-
dants about the source and availability of whichever ACTs they
had available, client preferences for AM and stock-out issues. A
short questionnaire was administered to whoever was selling in
the shop on the day of visit to the shop.
Statistical methods
All data were checked for completeness and consistency after
which they were double entered into EPI Data version 3.10
(EpiData Association, Odense, Denmark) followed by validation
of the data entered. Discrepancies were resolved by retrieving
the hard copy of the data collection instruments. Data cleaning
and analysis were completed using Stata version 12.0 (Stata
Corp, College Station, TX, USA). Statistical comparisons were
considered signiﬁcant at the 0.05 level. Analysis of the data
involved the calculation of simple frequencies and proportions
with exact conﬁdence intervals (CIs).
Table 1. Timeline for data collection in relation to implementation
of AMFm strategy in Ghana
Date Activity
June 2010 First Census (Census 1) is carried out
August 2010 The ﬁrst co-paid ACTs delivered to Ghana as part
of the AMFm Strategy
October 2010 Second Census (Census 2) is carried out
April 2013 Final Census (Census 3) is carried out
ACT: artemisinin combination therapy; AMFm: Affordable Medicines
Facility – malaria
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Ethical considerations
Ethical approval was obtained from the Ethics Review
Committees of the Ghana Health Service (GHS) in Ghana and the
London School of Hygiene & Tropical Medicine. Permission was
sought from the Dangme West District Health Management Team.
Informed consent was sought from the owners of the chemical
shops who participated in the study. All study records, including
shops and health facilities, were identiﬁed by means of study IDs.
Results
Fifty-three chemical shops and 3 pharmacies out of 62 existing
shops participated in the study, which took place at different
time points spanning the period June 2010 to February 2013.
Overall, there were 398, 388 and 442 different brands of AM
in the shops during the 3 censuses, respectively.
Availability of quality assured ACTs
Antimalarials were classiﬁed into four groups as follows: Quality
Assured ACTs (QUAACTs), artemisinin monotherapies, non-
artemisinin monotherapies, and herbal-based AM. These four
categories cover the types of AM on the market. The QAACTs are
WHO recommended pre-qualiﬁed ACTs, while the herbal-based
ones are locally manufactured AM from herbs, which are very
popular, especially in the rural areas. Availability of ACTs
increased over the period, comprising 16.6%, 42.5% and 47.7%
of AM in stock in all shops, respectively. Although QUAACTs were
not found in any shop during the ﬁrst census they comprised
80.0% (124/155) and 87.2% (184/211) of all ACTs during the
second and third censuses, respectively. An increase was seen in
the proportion of all AMs that were ACTs, over time. Data are
summarised in Table 2.
The proportion of non-artemesinin therapies of all the AM in
stock initially dropped sharply from 34.2% (136/398) to 6.9%
(27/388) by the second census. By the third and most recent cen-
sus, the proportion had increased back slightly to 9.5% (42/442).
Artemisinin monotherapies comprised 9.5% (38/398), 4.6% (18/
388) and 3.4% (15/442) of all AM available in the three time peri-
ods, suggesting that this change was sustained. Stocks of herbal-
based AM preparations were relatively high, forming on average,
40–45% of all AM in stock in the shops. This did not change sub-
stantially over the period, constituting 39.7% (158/398), 45.9%
(178/388) and 39.4% (174/442) of AM during the three censuses,
respectively, so were the same before and 2.5 years after AMFm
was started (Figure 1).
At the time of the survey coinciding with the last census, out
of the 442 different brands of AM found in the 56 shops, 39.4%
(174/442) were herbal preparations as compared to 47.7%
(211/442) ACTs. QUAACTs were the most sold type of AM for
both children and adults. The most sold AM for adults in the
2 months preceding the survey were said by 15 of the 56 shops to
be artesunate-amodiaquine (26.8%) and artemether-lumefantrine
(26.8%), respectively. For children, however, artesunate-amodiaquine
was mentioned by 18 shops (32.1%) as compared to artemether-
lumefantrine by 10 (17.9%) out of the 56 shops. Overall, 66.1%
(37/56) of the shops said they had QUAACTs in stock on the day
of the survey. Most of the QUAACTs available were artemether-
lumefantrine (59.5% of all QUAACTs). Overall, 55.4% (31/56) of
shops admitted to having experienced stock-outs of QUAACTs in
the preceding 2 months; most of them (12/31; 38.7%) for a 1–2
week period. Only 16 of the 56 shops (28.6%) had not experi-
enced any stock outs of the QUAACTs. Buying and selling prices of
QAACTs had increased by 40–100% and shopkeepers attributed
this mainly to the scarcity of the commodity and also to some
degree, distributors regulating how much they sold to any one
shop (Table 3).
Prices of antimalarials
Generally, adult AM were bought and sold at higher prices at all
times. When the AMFm medicines ﬁrst arrived, shop attendants
bought the QUAACTs for children at a mean price of 0.79 ghs
(US$0.53) and sold them at 1.26ghs (US$0.84). For adults they
bought and sold them at 1.05ghs (0.70USD) and 1.61 ghs
(1.07USD), respectively. However, 2.5 years later they were buy-
ing the children’s doses at 1.20 ghs (US$0.80) and selling them
Table 2. Availability of various classiﬁcations of antimalarials in chemical shops in the Dangme West District at different time periods
Indicators Time periods
Census 1 (2 months pre-AMFm)
n (%)
Census 2 (2 months post AMFm)
n (%)
Census 3 (2.5 years post AMFm)
n (%)
Number of antimalarial brands in the
shops
398 388 442
ACTs 66 (16.6%) 155 (39.9%) 211 (47.7%)
QUAACTs NA 124(32.0%) 184 (41.6%)
Artemisinin monotherapies 38 (9.5%) 18 (4.6%) 15 (3.4%)
Non-artemisinin therapies 136 (34.2%) 27 (6.9%) 42 (9.5%)
Herbal-based antimalarials 158 (39.7%) 178 (45.9%) (174) 39.4%
ACT: artemisinin combination therapy; AMFm: Affordable Medicines Facility – malaria; NA: not applicable; QAACT: quality assured artemisinin
combination therapy
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at 1.78ghs (US$1.19) while those of adults were being bought
and sold at mean prices of 1.65ghs (US$1.10) and 2.29 ghs (US
$1.53), respectively. The shop attendants said they sometimes
were only able to obtain the AMFm medicines if they purchased
other slow moving medicines since the distributors carried out
conditional sales. This contributed to the price of the AM going
up in order to cover the loss they would make on the cost of the
other medicine; some which were likely to expire.
Percentage mark-up on adult QUAACTs were lower 2.5 years
after the AMFm was introduced as compared to the time the
medicines ﬁrst arrived (41.3% vs 54.0%). This may have been
due to the fact that the prices at which shopkeepers bought the
QUAACTs had gone up considerably over time and they did not
feel able to increase the prices of the medicines to the extent
that would provide them with the same mark up as before. For
children, the change in percentage mark-up was minimal
(49.4% vs 58.2%).
Discussion
Some countries are considering putting some of their funds
from the Global Fund into the private sector as this is where
many patients with malaria go.15 AMFm was the ﬁrst major
attempt to do this for malaria on a widespread basis. Of the
four main objectives of AMFm, in this area of Ghana during this
study there was reasonable success in two: to increase ACT
availability in the private sector, although stock outs remained a
major problem; and to ‘crowd out’ oral artemisinin monother-
apies. In this area of Ghana there was only a slight increase in
affordability. Initial gains in these domains were broadly sus-
tained over the subsequent 2.5 years, but not improved upon.
Stocking of untested herbal products, which are heavily pro-
moted through the media for malaria, was unchanged.
Ghana is a good place to test AMFm concepts of subsidy of
key commodities in the private sector, as it has a relatively well
regulated public sector but also a thriving private sector where
many patients go. Early studies suggested that the subsidy
might not reach rural areas - here, as in some other sites, it
did.16,17 Several previous assessments of AMFm have either only
looked at the ﬁrst year after implementation, which can exam-
ine initial effect but not sustained effect, or used cross-sectional
studies at a single point in time.5,18
A decision by the Global Fund to incorporate AMFm into regu-
lar funding over the 2012–13 period (so countries have to trade
off funding for public sector support and private sector subsidy)
means the mechanism has now changed signiﬁcantly, but the
principles of subsidy in the private sector remain the same.
The issue of stock outs (55% of shops in the preceding
2 months in the last time period) was however a serious one,
and had an impact on both availability and price. It is probably
the reason why prices did not drop further. The last time period is
the most interesting one as it represents the new normal state
after initial euphoria and inevitable startup problems. The fact
Figure 1. Changes in proportions of types of antimalarials found in chem-
ical shops at three different time periods (June 2010, October 2010 and
April 2013). ACT: artemisinin combination therapy; AM: antimalarial;
AMFm: Affordable Medicines Facility - malaria. This ﬁgure is available in
black and white in print and in color at International Health online.
Table 3. Price of various classiﬁcations of antimalarials in chemical shops in the Dangme West District at different time periods
Indicators Costs
Census 1 (2 months pre-AMFm) Average
cost [range] in Ghana cedis
Census 2 (2 months post AMFm)
Average cost [range] in Ghana cedis
Census 3 (2.5 years post AMFm)
Avg cost [range] in Ghana cedis
Number of antimalarial
brands in the shops
398 388 442
QAACTs NA 2.87 [1.00–3.00] 3.85 [1.50–7.00]
Other ACTs 4.61 [0.50–13.00] 4.92 [1.5–15.00] 5.56 [1.00–15.00]
Artemisinin monotherapies 3.04 [2.50–6.00] 3.16 [1.20–3.80] 3.66 [3.00–5.00]
Non-artemisinin therapies 1.02 [1.00–13.50] 1.59 [0.30–5.50] 1.45 [0.50–4.00]
Herbal-based antimalarials 2.14 [1.50–5.00] 4.35 [3.00–7.00] 4.52 [2.40–8.00]
ACT: artemisinin combination therapy; AMFm: Affordable Medicines Facility – malaria; NA: not applicable; QAACT: quality assured artemisinin
combination therapy
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that stock outs were still occurring at this rate over 2 years later
cannot be ascribed to initial teething problems. In their
Tanzanian study, Cohen and others found that promotions and
advertisements on the radio increased awareness of ACTs, and
possibly increased desirability for the shopkeepers to stock
them.16 Improvements in communication can help raise aware-
ness of AMFm products, and could be used to counter the use of
untested herbal products, but in the absence of secure drug sup-
ply this will only have limited impact.19 This is especially import-
ant as the herbal-based AM are freely advertised on radio in this
setting and for many people, especially in the rural areas, these
would be the AM they would know by name. Client preferences
may inﬂuence which AM shopkeepers stock most16 and this may
explain why in this setting, herbal-based AM constituted, on aver-
age, 40% of all AM stocked.
The study inevitably has limitations. In common with all
before-and-after designs this study can only demonstrate asso-
ciation, not causality. The very rapid change over the AMFm peri-
od followed by little change thereafter does however suggest
AMFm and associated publicity was the main cause of the
change in availability of drugs, and supports the ﬁndings of ini-
tial assessments of AMFm during its introduction elsewhere in
Africa.20 The study was able to examine three of AMFm’s aims
over a 2.5 year period after AMFm was introduced: to increase
ACT affordability; to increase ACT availability; and to ‘crowd out’
oral artemisinins. It is not able directly to examine the ﬁnal one,
to increase ACT use, and there is evidence that in some settings
increasing availability of affordable ACTs in the private sector
does not in itself necessarily increase use, although in others it
has been found to.21,22
Conclusions
AMFm was initially partially successful in its aims in this area in
increasing availability of ACTs and helping crowd out artemisinin
monotherapy - this study shows that initial gains were sus-
tained 2.5 years later but not improved on. In order to prevent
reversal of the gains in malaria control over the last decade,
consistent supply of QAACTs to the private retail sector must be
assured. Stock outs (limiting supply for existing demand) may
play a major role in the price of ACTs as well as reducing avail-
ability directly. The continuing popularity of unproven herbal
remedies for malaria is a concern and AMFm seems to have
made little difference to this in Ghana.
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